FDA announces recall of more than 50,000 infusion pumps

Smiths Medical, maker of the Medfusion syringe pump, is issuing another recall for the devices after reports of persistent issues with earlier versions of the software used to run the pumps

A statement from the FDA says the recall is a correction, not a product removal, and relates to more than 50,000 units of the Model 4000 syringe pumps distributed from November 2010 through July 2023.

If the software hasn’t been properly updated, the alarm system, control screen and pump mechanism may fail, resulting in delayed or interrupted care delivery.

There’s been one reported injury and no deaths due to the issue.

Providers should locate all affected pumps and double-check for the most current Medfusion software.

This latest recall from Smiths Medical follows similar notices about software issues for both its Medfusion 3500 and 4000 syringe infusion pumps.

A 2022 recall listed eight separate potential software issues, including failures of the alarm and device’s internal clock. Seven serious injuries and one death were reportedly related to these software malfunctions.

Below are the ongoing potential issues flagged in the current recall, along with impacted Medfusion 4000 software versions:

  • Delivery During Motor Not Running High Priority Alarm (v1.0.0, v1.1.0, v1.1.1, v1.1.2)
  • Re-administered Loading Dose (v1.0.0, v1.1.0, v1.1.1, v1.1.2),
  • Incorrect Critical Data Failure Alarm,
  • Interruption of Bolus or Loading Dose Delivery (v1.0.0, v1.1.0, v1.1.1, v1.1.2),
  • Incorrect Total Bolus/Loading Dose Displayed (v1.1.0, v1.1.1, v1.1.2),
  • Volume Limit Before Bolus/Loading Dose Complete (v1.1.2),
  • Drug Library Lower Limit Displayed Incorrectly (v1.6.0, v1.6.1),
  • Depleted Battery Alarm (All versions previous to v1.6.5),
  • Loss of Wireless Connectivity (v1.5.0, v1.5.1, v1.6.0, v1.6.1, v1.6.4),
  • PharmGuard Server Password (v2.3, v2.4, v2.5).
Evan Godt
Evan Godt, Writer

Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.